Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and a Waiver under 21 U.S.C. §355 (n)(4)

Carol Koski, M.D.

Committees: Anti-Infective Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee

Meeting Dates: December 14-15, 2006

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to the overall benefit to risk considerations for the approved product, Ketek (telithromycin), new drug application (NDA) 21-144, manufactured by Sanofi-Aventis with the current indications of acute bacterial exacerbations of chronic bronchitis, acute bacterial sinusitis, and community acquired pneumonia, I am eligible to receive a waiver under 21 U.S.C. §355 (n)(4). I understand that this financial interest did not require an individual waiver under 18 U.S.C. 208(b)(3) as the interest in a publicly traded security is less than $15,000 and thus covered by a regulatory exemption issued by the Office of Government Ethics at 5 CFR 2640.202.

Type of Interest	Nature	Magnitude
Stock	Competing Firm	Valued from $5,001 to $25,000

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of this interest the waiver is not valid.

/s/
Signature of SGE

11/9/06
Date